The maintenance inhalers available for obstructive lung disease are long-acting beta-agonists (LABAs), long-acting muscarinic antagonists (LAMAs), and inhaled corticosteroids (ICSs). We use all three ...
Please provide your email address to receive an email when new articles are posted on . This analysis spanned from 2016 to 2022. Nearly 50% of patients were initially prescribed LABA/inhaled ...
Among patients with chronic obstructive pulmonary disease who received prior treatment with multiple-inhaler triple therapy, single-inhaler triple therapy was effective in improving health status and ...
M. Bradley Drummond, MD, MHS, professor of medicine, University of North Carolina at Chapel Hill, shares promising results of ensifentrine in helping patients with insufficient chronic obstructive ...
Among patients with blood eosinophil counts greater than or equal to 150 cells/µL, the reduction in the annual rate of moderate to severe COPD exacerbations was found to be nominally significant. The ...
Compared with tezepelumab, solrikitug demonstrated unique epitope binding and superior potency across several assays. Researchers from Uniquity Bio and Mosaic Biosciences conducted head-to-head in ...
Many patients with chronic obstructive pulmonary disease (COPD) have uncontrolled disease despite appropriate use of triple therapy. These patients often exhibit type 2 inflammation, as indicated by ...
Treatment with dupilumab reduced the annualized rate of moderate or severe COPD exacerbations by 30% in the BOREAS trial and 34% in the NOTUS trial compared with placebo. The Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results